High mobility group protein-1 (HMG-1) is a unique activator of p53

Genes and Development

Volumn 12, Issue 4, 1998, Pages 462-472

  Jayaraman, Lata ^a,c   Moorthy, Narayani Chandra ^a   Murthy, Kanneganti G K ^a   Manley, James L ^a   Bustin, Michael ^b   Prives, Carol ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

DNA binding activation; HMG 1; P53 protein; Transcription

Indexed keywords

DNA; HIGH MOBILITY GROUP PROTEIN; HISTIDINE; MUTANT PROTEIN; NUCLEOPROTEIN; PROTEIN P53; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; TRANSACTIVATION;

EID: 0032520175     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.12.4.462     Document Type: Article

References (57)

1. Agarwal, A. and D.G. Schatz. 1997. RAG1 and RAG2 form a stable postcleavage synaptic complex with DNA containing signal ends in V(D)J recombination. Cell 89: 43-53.
2. Balagurumoorthy, P., H. Sakamoto, M.S. Lewis, N. Zambrano, G.M. Clore, A.M. Groneborn, E. Appella, and R.E. Harrington. 1995. Four p53 DNA-binding domain peptides bind natural p53 response elements and bend the DNA. Proc. Natl. Acad. Sci. 92: 8591-8595.
3. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. mdm2 expression is induced by wild type p53 activity. EMBO J. 12: 461-468.
4. Baxevanis, A.D. and D. Landsman. 1995. The HMG-1 box protein family: Classification and functional relationships. Nucleic Acids Res. 23: 1604-1613.
5. Bazett-Jones, D.P., B. LeBlanc, M. Herfort, and T. Moss. 1994. Short-range DNA looping by the Xenopus HMG-box transcription factor, xUBF. Science 264: 1134-1137.
6. Bianchi, M.E., M. Beltrame, and G. Paonessa. 1989. Specific recombination of cruciform DNA by nuclear protein HMG-1. Science 243: 1056-1059.
7. Buckbinder, L., R. Talbott, S. Velasco-Miguel, I. Takenaka, B. Faha, B.R. Seizinger, and N. Kley. 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649.
8. Bustin, M. 1989. Preparation and application of immunological probes for nucleosomes. Methods Enzymol. 170: 214-251.
9. Bustin, M. and R. Reeves. 1996. High mobility group proteins. Prog. Nucleic Acids Res. Mol. Biol. 54: 35-100.
10. Chen, J., V. Marechal, and A.J. Levine. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13: 4107-4114.
11. Cho, Y., S. Gorina, P.D. Jeffery, and N.P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265: 346-355.
12. Dignam, J.D., P.L. Martin., B.S. Shastry, and R.G. Roeder. 1983. Eukaryotic gene transcription with purified components. Methods Enzymol. 101: 582-598.
13. El-Diery, W.S., S.E. Kern, J.A. Pietenpol, K.W. Kinzler, and B. Vogelstein. 1992. Definition of a consensus binding site for p53. Nature Genet. 1: 45-49.
14. El-Diery, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
15. Friedlander, P., Y. Haupt, C. Prives, and M. Oren. 1996. A mutant p53 that discriminates between p53 responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16: 4961-4971.
16. Giese, K., A. Amsterdam, and R. Grosschedl. 1991. DNA-binding properties of the HMG domain of the lymphoid-specific transcriptional regulator Lef-1. Genes &. Dev. 5: 2567-2578.
17. Ge, H. and R.G. Roeder. 1994. The high mobility group protein HMG-1 can reversibly inhibit class II gene transcription by interaction with the TATA-binding protein. J. Biol. Chem. 269: 17136-17140.
18. Gottlieb, M.T. and M. Oren. 1996. p53 in growth control and neoplasia. Biochim. Biophys. Acta 1287: 77-102.
19. Grosschedl, R., K. Giese, and J. Pagel. 1994. HMG domain proteins: Architectural elements in the assembly of nucleoprotein structures. Trends Genet. 10: 94-100.
20. Halazonetis, T.D., L.J. Davis, and A.N. Kandil. 1993. Wild-type p53 adopts a "mutant"-like conformation when bound to DNA. EMBO J. 12: 1021-1028.
21. Hamada, H. and M. Bustin. 1985. Chromosomal proteins HMG-1 and -2 distinguish between S1 sensitive sites in super-coiled DNA. Biochemistry 24: 1428-1433.
22. Huges, E.N., B.N. Engelsberg, and P.C. Billings. 1992. Purification of a nuclear protein that binds cis-platinum damaged DNA. J. Biol. Chem. 267: 13520-13527.
23. Hupp, T.R. and D.P. Lane. 1994. Allosteric activation of latent p53 tetramers. Curr. Biol. 4: 865-875.
24. Hupp, T.R., D.W. Meek, C.A. Midgley, and D.P. Lane. 1992. Regulation of the specific DNA binding function of p53. Cell 71: 875-886.
25. Hupp, T.R., A. Sparks, and D.P. Lane. 1995. Small peptides activate the latent sequence specific DNA binding function of p53. Cell 83: 237-245.
26. Jayaraman, L. and C. Prives. 1995. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81: 1021-1029.
27. Jayaraman, L., K.G.K. Murthy, C. Zhu, T. Curran, S.Xanthoudakis, and C. Prives. 1997a. Identification of redox/ repair protein Ref-1 as a potent activator of p53. Genes & Dev. 11: 558-570.
28. Jayaraman, L., E. Freulich, and C. Prives. 1997b. Functional dissection of the p53 tumor suppressor protein. Methods Enzymol. 283: 245-256.
29. Kastan, M.B., Q. Zhan, W.S. El-Deiry, F. Carrier, T. Jacks, W.V. Walsh, B.S. Plunkett, B. Vogelstein, and A.J. Fornace Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataxia-Telangiectasia. Cell 71: 587-597.
30. Ko, L.J. and C. Prives. 1996. p53: Puzzle and paradigm. Genes & Dev. 10: 1054-1072.
31. Landsman, D. and M. Bustin.(1993. A signature for the HMG-1 box DNA-binding proteins. Bioessays 15: 539-546.
32. Lee, S., B. Elenbaas, A. Levine, and J. Griffith. 1995. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81: 1013-1020.
33. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and development. Cell 88: 323-331.
34. Miyashita, T. and J.C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299.
35. Nagaich, A.K., E. Appella, and R.E. Harrington. 1997a. DNA bending is essential for the site-specific recognition of DNA response elements by the DNA binding domain of the tumor suppressor protein p53. J. Biol. Chem. 272: 14842-148949.
36. Nagaich, A.K., V.B. Zhurkin, H. Sakamoto, A.A. Gorin, G.M. Clore, A.M. Gronenborn, E. Appellam, and R.E. Harrington. 1997b. Architectural accommodation in the complex of four p53 DNA binding domain peptides with the p21/waf1/cip1 DNA response element. J. Biol. Chem. 272: 14830-14841.
37. Ogawa, Y., S. Aizawa, H. Shirakawa, and M. Yoshida. 1995. Stimulation of transcription accompanying relaxation of chromatin structure in cells overexpressing high mobility group 1 protein. J. Biol. Chem. 270: 9272-9280.
38. Okamoto, K. and D. Beach. 1994. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J.13: 4816-4822.
39. Oñate, S.A., P. Prendergast, J.P. Wagner, M. Nissen, R. Reeves, D.E. Pettijohn, and D.P. Edwards. 1994. The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences. Mol. Cell Biol. 14: 3376-3391.
40. Paull, T., M. Haykinson, and R.C. Johnson. 1993. The non-specific DNA-binding and bending proteins HMG-1 and HMG-2 promote the assembly of complex nucleoprotein structures. Genes & Dev. 7: 1521-1534.
41. Pil, P.M. and S.J. Lippard. 1992. Specific binding of chromosomal protein HMG-1 to DNA damaged by the anticancer drug cisplatin. Science 256: 234-237.
42. Pil, P.M., C.S. Chow, and S.J. Lippard. 1993. High mobility group protein 1 mediates DNA bending as determined by ring-closures. Proc. Natl. Acad. Sci. 90: 9465-9469.
43. Romani, M., T.C. Rodman, G. Vidali, and M. Bustin. 1979. Serological analysis of the species specificity of the high mobility group proteins. J. Biol. Chem. 254: 2918-2922.
44. Sawchuck, D.J., F. Weis-Garcia, S. Malik, E. Besmer, M. Bustin, M.C. Nussenzweig, and P. Cortes. 1997. V(D)J recombination: Modulation of RAG1 and RAG2 cleavage activity on 12/23 substrates by whole cell extract and DNA-bending proteins. J. Exp. Med. 185: 2025-2032.
45. Shaw, P., J. Freeman, R. Bovey, and R. Iggo. 1996. Regulation of specific DNA binding by p53: Evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 12: 921-930.
46. Shieh, S-Y., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by mdm2. Cell 91: 325-334.
47. Singh, J. and G.H. Dixon. 1990. High mobility group proteins 1 and 2 function as general class II transcription factors. Biochemistry 29: 6295-6302.
48. Tremethick, D.J. and P.L. Molloy. 1986. High mobility group proteins 1 and 2 stimulate transcription in vitro by RNA polymerase II and III. J. Biol. Chem. 261: 6986-6992.
49. _. 1988. Effects of high mobility group proteins 1 and 2 on initiation and elongation of specific transcription by RNA polymerase II in vitro. Nucleic Acids Res. 16: 11105-11122.
50. van Gent, D.C., K. Hiom, T.T. Paull, and M. Gellert. 1997. Stimulation of V(D)J cleavage by high mobility group proteins. EMBO J. 16: 2665-2670.
51. Verrier, C.S., N. Roodi, C.J. Yee, L.R. Bailey. R.A. Jensen, M. Bustin, and F.F. Parl. 1997. High-mobility group (HMG) protein and TATA-binding protein-associated factor TAF(II)30 affect estrogen receptor-mediated transcriptional activation. Mol. Endochrinol. 11: 1009-1019.
52. Vogelstein, B. and K.W. Kinzler. 1992. p53 function and dysfunction. Cell 70: 523-526.
53. Wang, Y., J.F. Schwedes, D. Parks, K. Mann, and P. Tegtmeyer. 1995. Interaction of p53 with its consensus DNA-binding site. Mol. Cell. Biol. 15: 2157-2165.
54. Wu, X., J.H. Bayle, D. Olson, and A.J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes & Dev. 7: 1126-1132.
55. Zappavigna, V., L. Falciola, M. Citterich, F. Mavilio, and M.E. Bianchi. 1996. HMG-1 interacts with HOX proteins and enhances their DNA binding and transcriptional activation. EMBO J. 15: 4981-4991.
56. Zauberman, A., A. Lubp, and M. Oren. 1995. Identification of p53 target genes through immune selection of genomic DNA: The cyclin G gene contains two distinct p53 binding sites. Oncogene 10: 2361-2366.
57. Zwilling, S., H. Konig, and T. Wirth. 1995. High mobility group protein 2 functionally interacts with the POU domains of octomer transcription factors. EMBO J. 14: 1198-1208.